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Introduction
During angiogenesis, a complex coordination of cues from 
 cytokines, growth factors, proteinases, and integrins mediate 
cellular changes to control the processes of sprouting, lumen 
formation, and proliferation (Davis et al., 2002; Carmeliet, 
2005; Davis and Senger, 2005). Once networks of endothelial 
cell (EC)–lined tubes are formed, the stabilization of these 
structures is regulated by support cells such as pericytes  (Orlidge 
and D’Amore, 1987; Jain, 2003; von Tell et al., 2006). In PDGF-B 
and -β receptor knockout mice, the lack of pericyte recruit-
ment results in vascular instability and embryonic lethality 
(Lindahl et al., 1997; Hirschi et al., 1998; Hellstrom et al., 1999, 
2001; Jain, 2003). A molecular understanding of how pericyte–
EC interactions lead to EC tube stability is not well understood 
and is an emerging fi eld in vascular biology (Jain, 2003; Davis 
and Senger, 2005; von Tell et al., 2006).
Matrix metalloproteinases (MMPs) regulate many biolog-
ical processes, including ECM degradation, proteolysis of cell 
surface proteins, proteinase zymogen activation, liberation of 
growth factors, and regulation of tissue morphogenesis (Nagase 
and Woessner, 1999; Davis et al., 2002; Kheradmand and Werb, 
2002), which includes vascularization (Pepper, 2001; Davis 
et al., 2002). Membrane-type (MT) MMPs but not soluble 
MMPs have been shown to play a critical role in cellular inva-
sion through 3D matrices by degrading ECM proteins at the cell 
surface–ECM interface while maintaining the integrity of the 
surrounding ECM scaffold (Hotary et al., 2000, 2002; Lafl eur 
et al., 2002; Bayless and Davis, 2003; Chun et al., 2004). MMPs 
are controlled by various inhibitors, including tissue inhibitor of 
metalloproteinases-1–4 (TIMPs-1–4; Baker et al., 2002). TIMPs 
have been shown to regulate angiogenesis, wound repair, and 
tumor metastasis (Anand-Apte et al., 1997; Lafl eur et al., 2001; 
Spurbeck et al., 2002; Seo et al., 2003; Stetler-Stevenson and 
Seo, 2005), and a balance of MMPs and TIMPs appears to 
be critical during these events. Interestingly, MMPs appear to 
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genesis and  regression in three-dimensional collagen 
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technology, the suppression of EC TIMP-2 and pericyte 
TIMP-3 expression leads to capillary tube regression 
in these cocultures in a matrix metalloproteinase-1 
(MMP-1)–, MMP-10–, and ADAM-15 (a disintegrin and 
 metalloproteinase-15)–dependent manner. Furthermore, 
we show that EC tube morphogenesis  (lumen formation 
and invasion) is primarily controlled by the TIMP-2 and -3 
target membrane type (MT) 1 MMP. Additional targets 
of these inhibitors include MT2-MMP and ADAM-15, 
which also regulate EC invasion. Mutagenesis experiments 
reveal that TIMP-3 requires its proteinase inhibitory 
 function to induce tube stabilization. Overall, these data 
reveal a novel role for both TIMP-2 and -3 in the pericyte-
 induced stabilization of newly formed vascular networks 
that are predisposed to undergo regression and reveal 
speciﬁ c molecular targets of the inhibitors regulating 
these events.
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 contribute to tissue regression in the mammary gland (Green 
and Lund, 2005), vasculature (Davis et al., 2001; Saunders 
et al., 2005; Davis and Saunders, 2006), and during the  menstrual 
 cycle (Curry and Osteen, 2003). In this study, we present the 
novel concept that EC-derived TIMP-2 and pericyte-derived 
TIMP-3 coregulate capillary tube stabilization by the inhibition 
of key EC targets such as MT1-MMP, ADAM-15 (a disintegrin 
and metalloproteinase-15), MMP-1, and MMP-10, which normally 
control EC tube formation and/or regression.
Results
TIMP-2 and -3 markedly inhibit EC invasion 
and tubular morphogenesis events in 3D 
collagen matrices
Using an in vitro model of angiogenic sprouting, human ECs 
invade 500 μm into 3D collagen matrices over a 48-h period 
(Fig. 1 A). This invasion response is completely inhibited by 
TIMP-2 and -3 (Fig. 1, A and B) but not by TIMP-1. Although 
control and TIMP-1–treated invading ECs form lumenal struc-
tures, no lumen formation is seen from TIMP-2– or -3–treated 
invading ECs (Fig. 1 B). Similar results using ECs transfected 
with lentiviral vectors expressing control GFP, TIMP-1, or 
TIMP-3 were observed (Fig. S1 A, available at http://www.jcb.
org/cgi/content/full/jcb.200603176/DC1).
Time-lapse videos were performed with ECs suspended as 
individual cells within collagen matrices (vasculogenesis-like 
 assay; Davis et al., 2002) over a 48-h period and treated with 
TIMP-1, -2, or -3 versus the control (Videos 1–4, avail able 
at http://www.jcb.org/cgi/content/full/jcb.200603176/DC1). 
Photographs from these videos are shown at 48 h of culture 
(Fig. 1 C). ECs treated with TIMP-2 and -3 fail to form tubes (i.e., 
no  lumen structures observed) and instead send out fi ne processes 
over this time course (Fig. 1 C, arrowheads; and Videos 1–4). 
Addition of the chemical MMP inhibitor GM6001 shows essen-
tially identical results, suggesting that these effects are likely the re-
sult of proteinase inhibition (Video 5). In contrast, obvious lumenal 
and tube structures are observed in the control and TIMP-1–treated 
cultures (Fig. 1 C). Quantitation of the sprouting assay as well as 
quantitation of the vasculogenesis assay  reveals marked blockade 
of invasion and lumen formation by both TIMP-2 and -3 (Fig. 1 D). 
These results demonstrate that both TIMP-2 and -3 completely 
 inhibit EC invasion and lumen formation (perhaps indicating a 
common molecular target), whereas TIMP-1 has no effect.
Figure 1. EC invasion and tubular morphogenesis in 
3D collagen matrices are inhibited by TIMP-2 and -3. 
(A) ECs were seeded onto collagen matrices and stim-
ulated to invade for 48 h in response to 1 μM S1P in 
the absence (control) or presence of 5 μg/ml TIMP-1, 
-2, or -3. Arrows indicate the EC monolayer; arrow-
heads point to the invading EC sprouts. Bar, 100 μm. 
(B) Plastic sections of these cultures are shown to illus-
trate the presence (control; TIMP-1) or absence (TIMP-2 
and -3) of EC lumenal structures (arrowheads). Arrows 
indicate the EC monolayer; arrowheads point to EC 
lumens. Bar, 40 μm. (C) ECs were suspended within 
collagen matrices and allowed to undergo morpho-
genesis and tube network formation for 48 h in the 
absence (control) or presence of 5 μg/ml TIMP-1, -2, 
or -3 using time-lapse microscopy. Arrows point to mul-
ticellular EC tube networks; arrowheads indicate ﬁ ne 
processes. Bar, 50 μm. (D) Graphs show the mean 
 invasion distance in micrometers (left) or the total 
 number of ECs forming lumens (right) ± SD (error 
bars) using time-lapse images at 48 h. *, P < 0.01 for 
TIMP-2– or -3–treated ECs compared with controls. 
HPF, high-powered ﬁ eld.
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TIMP-3 markedly blocks vasculogenesis 
and angiogenesis in mouse embryo cultures
To determine the ability of TIMP-3 to affect vessel formation 
in vivo, mouse embryo cultures were established from embry-
onic day (E) 7.5 to E9.5 in the presence of TIMP-1, TIMP-3, 
GM6001, and DMSO control (Fig. 2 A). Untreated, DMSO, 
and TIMP-1–treated cultures were photographed live at 48 h 
and exhibited the remodeling of capillary networks, large vitel-
line vessels at the origin in the embryo, and large vessels lead-
ing to capillaries. The large vitelline vessels (Fig. 2 A, insets) 
along with capillary networks stained positively for vascular 
 endothelial (VE) cadherin. TIMP-3– and GM6001–treated em-
bryos lacked vitelline vessels, exhibited an immature capillary 
plexus, and failed to turn. No large vessel structures were formed 
in GM6001– (unpublished data) or TIMP-3–treated  explants as 
compared with the untreated or TIMP-1–treated  explants. These 
data indicate that TIMP-3 treatment blocked the assembly of 
vascular structures in vivo, which directly correlated with our 
in vitro fi ndings.
TIMP-3 is expressed by perivascular 
mesenchymal cells and the visceral 
endoderm during early vascular 
development
RT-PCR analysis of embryonic region (E6.5 and E7.5), extra-
embryonic region (6.5× and 7.5×), and yolk sac (8.5 and 9.5 d) 
tissues during vascular development revealed that TIMP-3 was 
expressed abundantly in both embryonic and extraembryonic 
tissue as well as by the yolk sac at the time points indicated 
(Fig. 2 B). TIMP-3 showed increased expression up to E8.5, 
whereas TIMP-1 expression decreased over this time period. 
Immunofl uorescence imaging of visceral endoderm and meso-
derm sections of yolk sac at E8.5 and E9.5 revealed the 
 colo calization of TIMP-3 with angiopoietin-1 in perivascular mes-
enchymal cells (pericyte and vascular smooth muscle precur-
sors), which surround the early vascular tubes (Fig. 2 C). Also, 
strong staining for TIMP-3 was observed in the visceral endo-
derm, an  important supporting structure that controls develop-
ment of the early vasculature (Bohnsack et al., 2004). These 
staining distributions were confi rmed by in situ hybridization 
(unpublished data). Thus, the visceral endoderm and mesen-
chyme  surrounding EC tubes (stained with VE-cadherin; Fig. 
2 C) in the mesoderm may serve to control and stabilize 
EC tubular morphogenesis by delivering TIMP-3 to newly 
formed vascular tubes.
TIMP-3 stabilizes preexisting capillary tube 
networks by blocking tube formation and 
MMP-1–dependent tube regression
Because TIMP-3 completely inhibits EC tube morphogenesis, 
we asked whether TIMP-3 could induce the collapse and re-
gression of preexisting networks of capillary tubes. A previous 
study revealed that α2-integrin–blocking antibodies interfere 
with the formation of tubes but also cause the rapid collapse 
(within several hours) of previously formed tube networks 
(Davis et al., 2001). EC cultures were treated at different times 
with TIMP-1, -3, or blocking antibodies directed to the α2- 
and α5-integrin subunits (Fig. S2, available at http://www.jcb.
org/cgi/content/full/jcb.200603176/DC1). The treatment of 
EC cultures from 0–8 or 0–24 h with α2-integrin–blocking 
Figure 2. MT metalloproteinases are required 
for the remodeling of vascular networks in vivo 
during mouse vascular development, and TIMP-3 
is expressed by perivascular mesenchyme. 
(A) E7.5 cultures were established as described 
previously (Bohnsack et al., 2004) and, in ad-
dition, were incubated in the presence of 
5 μg/ml TIMP-1 or -3. Cultures were photo-
graphed live (left two panels) or were immuno-
stained (right) after 48 h for VE-cadherin 
expression. Magniﬁ ed live images from the 
boxed areas are shown in the adjacent panels 
for each treatment condition. (B) RT-PCR analy-
sis was performed on extraembryonic (X) 
and embryonic tissue (E) at the days indicated 
using primers speciﬁ c for TIMP-1, -3, and 
 control. (C) Tissue sections at the indicated 
times were stained with antibodies directed 
to TIMP-3, VE-cadherin, and angiopoietin-1 
(Ang-1). Bars, 100 μm.
JCB • VOLUME 175 • NUMBER 1 • 2006 182 
antibodies or TIMP-3 strongly inhibited intracellular vacuole 
and lumen formation (Fig. S2, A and B). TIMP-1 addition or 
blocking antibodies directed to the α5-integrin subunit had no 
effect and were identical to the control. The addition of these 
agents to preestablished EC networks (48 h) revealed that 
although α2-integrin–blocking antibodies completely col-
lapsed lumenal structures and tubular networks, TIMP-3 did 
not have this effect (Fig. S2 C). From these data, we hypothe-
sized that TIMP-3 may serve as a stabilizing signal by pre-
venting further morphogenic events and blocking the natural 
tendency of EC tubes to regress. A time-lapse experiment 
shown in Fig. S3 supports this conclusion in that TIMP-3 ad-
dition to preformed tubes does not cause collapse but retards 
further morphogenic progression, whereas TIMP-1 addition 
had no effect on either process.
We also tested the ability of TIMP-3 to block proteinase-
mediated regression of endothelial networks. We used a previ-
ously established model for EC network regression and collagen 
gel contraction (Davis et al., 2001; Saunders et al., 2005) in 
which ECs were allowed to assemble into tube networks for 
24 h before plasminogen (Plg) addition to activate pro–MMP-1 
and -10. Cultures were either left untreated (control) or were 
treated with TIMP-1 or -3. After 48 h, cultures were fi xed, and 
the percentage of collagen gel contraction was quantitated 
 (collagen gel contraction represents the end stage of capillary 
tubular network collapse after proteolysis of the collagen gel 
matrix scaffold). These data are shown in Fig. S2 D, and they 
support the concept that TIMP-3 functions to stabilize and pre-
vent the regression of EC networks. TIMP-1 also inhibits re-
gression events that are regulated by MMP-1 and -10, which is 
consistent with our previous observations (Davis et al., 2001; 
Saunders et al., 2005). TIMP-2 and GM6001 show essentially 
identical effects compared with TIMP-3 in these latter assays 
(unpublished data).
Marked production of TIMP-3 by pericytes 
and regulation of pericyte TIMP-3 
production by ECs in 3D collagen matrices
Pericytes are known to stabilize the developing or wound vascu-
lature (von Tell et al., 2006). We hypothesized that perhaps peri-
cytes deliver TIMP-3 to EC tubes to stabilize them. To evaluate 
TIMP-3 production by vascular cells, including EC, bovine ret-
inal pericytes (BRPs), and coronary artery smooth muscle cells 
(CASMCs), cells were cultured on plastic substrates and treated 
with or without TGF-β for 24 h (Fig. S1 B). Western blot ana-
lyses of cell lysates revealed that TIMP-3 was not produced by 
ECs. However, marked production of TIMP-3 was observed 
from pericytes and to a lesser degree by CASMCs.
Because pericytes appear to be a strong source of TIMP-3, 
3D cocultures were established with ECs and pericytes at vary-
ing pericyte/EC ratios using constant levels of ECs (Fig. 3 A). 
In addition, we performed the reverse experiment whereby per-
icytes were added at a constant level and ECs were added at 
varying levels (Fig. 3 B). As shown in Fig. 3 (A and B), increas-
ing the levels of pericytes in the presence of constant ECs or in-
creasing the levels of ECs with constant pericytes leads to a 
strong increase in TIMP-3 production. Interestingly, TIMP-3 is 
strongly produced by pericytes on plastic dishes (Fig. S1 B), but 
this production markedly decreases when they are cultured 
alone in 3D collagen matrices (Fig. 3 B). Importantly, the cocul-
ture of ECs with pericytes strongly induces TIMP-3 production 
by pericytes (Fig. 3, A and B). In contrast, it is clear that ECs are 
by far the predominant source of TIMP-2, TIMP-1, and PAI-1 
in this 3D model. Little production of these factors is seen from 
pericytes alone, whereas the strong production of each of these 
factors is observed with ECs alone. To evaluate this conclusion 
further, siRNA suppression experiments were performed using 
both ECs and pericytes in 3D culture to assess which cell type 
is producing each proteinase inhibitor. As shown in Fig. 3, 
Figure 3. Coculture of ECs with BRPs results in a marked 
induction of pericyte-derived TIMP-3 and a decreased pro-
duction of EC-derived MMP-1. (A) ECs were suspended 
in 3D collagen matrices and cultured alone or in the pres-
ence of varying amounts of BRPs relative to EC number for 
48 h before the collection of conditioned media or prepa-
ration of cell extracts. (B) Varying concentrations of 
ECs (relative to 100% EC culture) were cocultured with 
3 × 105 cells/ml BRPs or were cultured alone. Western 
blots for the indicated antigens were performed. (C) ECs 
treated with TIMP-2 siRNA were cocultured with BRPs 
treated with luciferase control siRNA (Luc) and vice versa 
as shown. PC, pericyte. (D) ECs transfected with TIMP-3 
siRNA were cocultured with BRPs transfected with Luc 
siRNA and vice versa as shown. (C and D) Western blots 
are shown to determine the indicated TIMP expression af-
ter treatment. (E) ECs were cultured alone or in the pres-
ence of 30% BRPs (relative to 100% ECs), CASMCs, or 
normal human dermal ﬁ broblasts (NHDFs) in the presence 
of 1 μg/ml plasmin for 48 h. Unstained cultures were 
photographed to assess the extent of regression and gel 
contraction. Bars, 500 μm.
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 siRNAs directed to these proteins show that ECs are the pre-
dominant source of TIMP-2, TIMP-1, and PAI-1, whereas peri-
cytes are the source of TIMP-3. Thus, it appears that TIMP-3 
production is markedly regulated by EC–pericyte interactions, 
whereas the other proteinase inhibitors do not appear to be 
 altered. Interestingly, pro–MMP-1 levels, which control capillary 
tube regression, are progressively decreased with increasing 
levels of pericytes in the cocultures (Fig. 3 A). In contrast, pro–
MMP-10 levels do not change under the same conditions.
Pericytes completely block MMP-1– 
and -10–dependent capillary tube regression 
events leading to capillary tube stabilization
To address whether pericytes are able to contribute to capillary 
tube stabilization through the blockade of MMP-1– and -10–
 dependent tube regression, cocultures were prepared, and quan-
titative analysis of tube regression over time was examined. 
To illustrate the coculture system, GFP-labeled ECs were co-
cultured with mRFP-labeled (Campbell et al., 2002) pericytes, 
which clearly shows the ability of pericytes to associate with 
developing EC tubes (Fig. 4 A). As shown in Fig. 4 B, the addi-
tion of pericytes induced a strong delay in regression until the 
addition of 20 or 30% pericytes relative to ECs where tube re-
gression is completely inhibited. To examine whether the tube 
regression event correlates with pro–MMP-1 or -10 activation, 
Western blots were performed (Fig. 4 B). The addition of 30% 
pericytes completely blocks MMP-1 and -10 activation in re-
sponse to Plg addition, indicating that proteinase inhibition is 
the most likely mechanism by which pericytes interfere with the 
capillary tube regression response (Fig. 4 B). To address whether 
pericytes were unique in their ability to block EC tube regres-
sion, 30% human fi broblasts or CASMCs were added, and nei-
ther cell type was able to block the regression response like the 
pericytes at this cell/EC percentage (Fig. 3 E).
EC-derived TIMP-2 and pericyte-derived 
TIMP-3 prevent capillary tube regression 
events (leading to tube stabilization) 
in EC–pericyte cocultures
To address the role of the different TIMPs and PAI-1 in this co-
culture model of pericyte-induced capillary tube stabilization, 
siRNA suppression was used. As shown in Fig. 5, siRNA sup-
pression of specifi c TIMPs in ECs versus pericytes was ob-
served relative to an actin control. In this experiment, ECs were 
treated with luciferase control, TIMP-1, or -2 siRNAs, whereas 
pericytes were treated with luciferase control or TIMP-3 siRNA. 
The different cell types were mixed in different combinations 
and were cultured in 3D collagen matrices at two pericyte/EC 
ratios of 30 or 50% pericytes relative to ECs (which previously 
completely inhibited capillary tube regression; Fig. 4). As 
shown in Fig. 5 B, at two different time points (3 or 6 d), siRNA 
suppression of EC TIMP-2 and pericyte TIMP-3 resulted in 
tube regression responses of the EC–pericyte cocultures. At 
later times of culture at 6 d, the suppression of EC TIMP-2 
alone resulted in a tube regression response in a coculture con-
taining 30% pericytes. At 3 d, the combination of EC TIMP-2 
and pericyte TIMP-3 strongly induced capillary tube regression. 
In 50% pericyte cocultures, the only combination of siRNAs 
that affected tube regression was EC TIMP-2 combined with 
pericyte TIMP-3. This data strongly argues that both EC- derived 
TIMP-2 and pericyte-derived TIMP-3 are required for EC–
 pericyte cocultures to stabilize capillary tubes.
Identiﬁ cation of molecular targets of 
TIMP-2 and -3 that control capillary tube 
stabilization: MT1-MMP is a key regulator of 
EC tube formation and invasion responses
A key question in our studies is what molecular targets are 
blocked by TIMP-2 and -3 that interfere with both tube formation 
(Fig. 1) as well as the tube regression response (Fig. 4). To ad-
dress this issue, we performed experiments with a series of poten-
tial targets of these TIMPs using an siRNA suppression approach. 
As shown in Fig. 6, we have suppressed the protein expression 
of a variety of MT-MMPs as well as ADAM proteinases and 
Figure 4. Pericytes markedly block EC tube regression via the inhibition 
of MMP-1 and -10. (A) EC or BRP stable cell lines expressing GFP or mRFP, 
respectively, were cocultured with 30% BRPs relative to ECs for 72 h be-
fore ﬂ uorescence photography. Pericytes (arrowheads) are shown associ-
ating with EC-lined tubes (arrows). Bar, 50 μm. (B) ECs were suspended in 
3D collagen matrices in the presence of an increasing concentration of 
BRPs (shown as the percentage relative to ECs). Cultures were supplied 
with standard media containing 2 μg/ml Plg. Cultures were monitored 
 every 4 h for EC tubular network collapse and collagen gel contraction. 
Data are reported as the mean percent collagen gel contraction ± SD 
 (error bars) at the indicated times (n = 8). (C) At 72 h, conditioned media 
were collected and analyzed for MMP-1 and -10 expression and activation 
via Western blotting. Arrows indicate proenzymes; arrowheads point to 
 activated enzymes.
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 assay system. Western blots show strong protein suppression of 
key enzymes (along with actin control) with biological activity in 
our system (Figs. 6 and 7). There was complete specifi city in this 
suppression in that only the indicated siRNA suppressed the ex-
pression of the appropriate protein and had no infl uence on any of 
the other proteinases using Western blot analysis. The MT1-
MMP siRNA is shown to markedly block tube and lumen forma-
tion compared with luciferase control and MT3-MMP siRNAs 
(Fig. 6 A). Interestingly, the morphology of MT1-MMP siRNA–
treated cells looks remarkably similar to ECs treated with TIMP-2 
or -3 as shown in Fig. 1 and in Videos 1–5. MT1-MMP siRNA–
treated ECs extend fi ne processes into the 3D collagen matrices 
but fail to form lumenal structures or tube networks. Quantitation 
of these results reveals that only MT1-MMP siRNA had a strong 
blocking infl uence (Fig. 7 A). In contrast, no other siRNA had a 
blocking infl uence, and ADAM-9 siRNA actually stimulated the 
EC lumen formation process, suggesting that it may normally be 
an inhibitor of these events. Overall, these data strongly show that 
the likely key target of TIMP-2 and -3 in vasculogenesis assays is 
MT1-MMP, which is known to be blocked by these two TIMPs 
(Baker et al., 2002). The inability of TIMP-1 to block in these 
 assays also supports this conclusion because it has no ability to 
block MT1-MMP (Baker et al., 2002).
To further confi rm this conclusion, we performed ELISA 
capture assays using GFP epitope-tagged MT1-MMP or TIMP-3 
to demonstrate binding interactions between the two proteins. As 
shown in Fig. 6 C, the strong binding of TIMP-2 and -3 is detected 
to GFP epitope-tagged MT1-MMP by capturing the complex on 
anti-GFP–coated wells in HEK293 cell cotransfection experi-
ments. The reverse experiment also shows the binding of MT1-
MMP to TIMP-3 in ECs when a TIMP-3–GFP fusion protein is 
expressed in ECs using a recombinant adenovirus. TIMP-3–GFP is 
captured onto wells, and the wells were probed with anti–MT1-
MMP antibodies to reveal the binding interaction (Fig. 6 C).
To further analyze the infl uence of these  metalloproteinase 
siRNAs, we performed two additional assays that mimic the 
process of angiogenesis whereby ECs invade into collagen 
 matrices from a matrix surface (Davis et al., 2002; Davis and 
 Senger, 2005). For these assays, we used two distinct stimuli to 
induce EC invasion and tube morphogenesis in 3D collagen 
 matrices. We previously reported that sphingosine-1 phosphate 
(S1P) induces EC invasion (Bayless and Davis, 2003), and, 
here, we report for the fi rst time that the chemokine stromal-
 derived factor-1α (SDF-1α) strongly induces invasion and tube 
morphogenesis in our system when it is incorporated into a 3D 
collagen matrix. This latter chemokine is known to synergize 
with VEGF in both developmental and pathological vascular 
morphogenic events (Ceradini et al., 2004; Kryczek et al., 
2005). It may represent a more physiologically relevant stimu-
lus than S1P in this type of assay system.
As shown in Fig. 7, MT1-MMP siRNA dramatically blocks 
the invasion stimulated by either S1P or SDF-1α. This is shown 
quantitatively in Fig. 7 (B and C) and through photographs in 
Figs. S4 and S5 (available at http://www.jcb.org/cgi/content/full/
jcb.200603176/DC1). Interestingly, MT2-MMP siRNA also in-
hibits SDF-1α invasion while partially inhibiting S1P invasion. 
Interestingly, ADAM-15 siRNA suppresses invasion selectively 
with SDF-1α–induced responses. ADAM-9 siRNA stimulates in-
vasion responses like the aforementioned vasculogenesis assay, 
whereas ADAM-17 siRNA partially stimulates the SDF-1α inva-
sion response. Collectively, these data show that MT1-MMP is 
required for EC tube formation in vasculogenic assays as well as 
in invasion and tube morphogenesis in response to two strong 
 invasion-promoting stimuli, SDF-1α and S1P. Both MT2-MMP 
and ADAM-15 appear to play a lesser but detectable role selec-
tively in SDF-1α–induced EC invasion responses.
MMP-1, MMP-10, and ADAM-15 regulate 
capillary tube regression responses in 3D 
collagen matrices
To address the role of various metalloproteinases in the capil-
lary tube regression response, we performed regression time 
courses with the siRNA-treated ECs over time (Fig. 8 A). 
Figure 5. EC-derived TIMP-2 and BRP-derived TIMP-3 are required for 
EC–pericyte interactions to stabilize EC tube networks. ECs were transfected 
with siRNAs targeting TIMP-1, TIMP-2, PAI-1, or luciferase control (Luc), 
and BRPs were transfected in a similar manner with siRNAs targeting TIMP-3 
or luciferase control. (A) Western blot analysis of EC-conditioned media 
and BRP cell lysates indicates the effectiveness of siRNA treatment on the 
expression of the indicated TIMPs as well as actin controls. (B and C) ECs 
were suspended in collagen matrices in the presence of 30 or 50% BRPs 
(relative to ECs) in the indicated combinations. EC tube network regression 
was induced with 1 μg/ml of activated human plasmin and was quanti-
tated at 3 or 6 d (reported as the mean percentage of gel contraction ± 
SD [error bars]). *, P < 0.01 compared with luciferase control; †, P < 
0.01 for EC TIMP-2 siRNA–treated ECs compared with other samples with 
50% BRPs. PC, pericyte.
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Marked delays in the regression response occurred with three 
siRNA treatments: MMP-1, MMP-10, and ADAM-15 (Fig. 8 A). 
Previously, we reported that MMP-1 and -10 both control capil-
lary tube regression (Saunders et al., 2005). ADAM-15, a known 
TIMP-3 target, appears to play a strong role in this process as 
well. A partial delay occurred with MT1-MMP–treated cells, 
which may relate to the fact that these cells fail to undergo sub-
stantial tube formation. EC tube formation is not blocked with 
MMP-1–, MMP-10–, or ADAM-15–treated cells. Interestingly, 
ADAM-9– and -17–treated ECs show accelerated regression 
 responses compared with control luciferase as well as ADAM-10 
and -12 treatments.
To address how these treatments affect pro–MMP-1 or -10 
activation, Western blots were performed (Fig. 8 B). MMP-1 
and -10 siRNA knockdown shows marked suppression of the 
respective proteins, whereas ADAM-15 knockdown appears to 
suppress the overall levels of both pro–MMP-1 and -10 as well 
as the activated forms of these two enzymes, which appears to 
account for the regression delay. The mechanism by which 
ADAM-15 suppression affects MMP-1 or -10 levels and activa-
tion is unclear. Interestingly, ADAM-9 and -17 suppression ap-
pears to accelerate the regression response by affecting MMP-1 
activation, whereby a greater proportion of activated pro–MMP-1 
is observed in both cases. Overall, these data suggest that 
three primary enzymes appear to play a central, required role in 
the MMP-dependent regression response (MMP-1, MMP-10, 
and ADAM-15). These metalloproteinases are all blocked by 
TIMP-3, whereas MMP-1 and -10 are known to be blocked by 
TIMP-2.
The ability of TIMP-3 to stabilize 
tubes is dependent on its proteinase 
inhibitory activity
To further confi rm that TIMP-3 acts as a stabilizing factor through 
blocking metalloproteinase targets, we performed site-directed 
mutagenesis of TIMP-3 using known mutations that interfere 
with its proteinase inhibitory activity (Langton et al., 1998; Brew 
et al., 2000). We mutated either cysteines 1, 3, or both and made 
lentiviral vectors that express these constructs in comparison with 
TIMP-1. Stable EC cell lines expressing these recombinant pro-
teins were selected, and each of the respective recombinant 
 proteins were produced at appropriate levels (Fig. 9 A). To ad-
dress whether the recombinant proteins infl uence tube formation 
or regression, we performed various biologic assays (Fig. 9, B–D). 
As shown in Fig. 9, TIMP-3 wild type is able to block lumen for-
mation (Fig. 9 B), invasion responses (Fig. 9 C), and capillary 
tube regression (Fig. 9 D). In contrast, increased TIMP-1 expres-
sion fails to block tube formation or invasion but completely in-
hibits tube regression through its known ability to inhibit MMP-1– 
and -10–dependent proteolytic events (Davis et al., 2001; Baker 
et al., 2002). The TIMP-3 mutants failed to block EC lumen 
 formation or invasion, suggesting that the proteinase inhibitory 
function of TIMP-3 is required for the ability of TIMP-3 to 
 stabilize tubes through interference with EC tube morphogenesis. 
Figure 6. MT1-MMP is a TIMP-2 and -3 target 
 required for EC tubular network formation in 3D 
 collagen matrices. ECs were treated with the indicated 
siRNAs and suspended in 3D collagen matrices for 
48 h before ﬁ xation for photography or quantitation. 
(A) Representative ﬁ elds of ECs treated with MT1-MMP, 
MT3-MMP, or luciferase control siRNAs. Bar, 100 μm. 
(B) ECs transfected with the indicated siRNAs were 
cultured for 24 h before the preparation of lysates for 
Western blot analysis of the indicated  proteinases or 
actin control (arrowhead). (C) ELISA capture assay 
showing interactions of MT1-MMP with TIMP-2 and -3. 
(left) HEK293 cells were cotransfected with MT1-
MMP–GFP fusion or MT1-MMP alone with TIMP-2, -3, 
or control plasmids, and lysates were made after 20 h. 
Lysates were incubated in microwells coated with an 
anti-GFP mAb and were probed with antibodies to 
TIMPs to detect binding interactions. (right) ECs were 
infected overnight with recombinant adenoviruses car-
rying TIMP-3–GFP or TIMP-3 alone, and lysates were 
prepared. Lysates were incubated in microwells 
coated with an anti-GFP mAb and were probed with 
an MT1-MMP antibody to detect binding interactions. 
Error bars represent SD.
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Surprisingly, the TIMP-3 C1S mutant retained its ability to block 
tube regression responses, whereas the TIMP-3 C3S mutant or 
C1SC3S double mutant did not. Overall, these data demonstrate 
that the proteinase inhibitory function of TIMP-3 is central to its 
ability to stabilize tubes through the blockade of tube morpho-
genesis and tube regression responses.
Discussion
EC-derived TIMP-2 and pericyte-derived 
TIMP-3 coregulate human capillary tube 
stabilization in 3D collagen matrices
There is considerable interest in the mechanism by which peri-
cytes stabilize capillary tubes during development and other 
vascular morphogenic events (Orlidge and D’Amore, 1987; 
Jain, 2003; von Tell et al., 2006). Much data support the concept 
that pericytes stabilize EC-lined tubes as a result of observa-
tions that tubes without associated pericytes are more suscepti-
ble to regression (Jain, 2003; von Tell et al., 2006). However, 
the molecular mechanisms that regulate these phenomena re-
main unclear. The data presented here propose a new concept in 
that pericyte-induced capillary tube stabilization can be medi-
ated, in part, by proteinase inhibition (Fig. 10). Our work sug-
gests that proteinase inhibition of both EC tube morphogenesis 
(leading to the cessation of morphogenesis) and tube regression 
is necessary to control tube stabilization.
Previous data from our laboratory support the concept that 
ECs undergoing the lumen formation process and assembling 
into 3D networks induce a gene program to regulate tube forma-
tion but also establish the conditions necessary for tube regres-
sion (Bell et al., 2001; Davis et al., 2002; Davis and Saunders, 
2006). In studies of EC network collapse of 3D collagen matri-
ces, ECs secrete high levels of a latent collagenase, pro–MMP-1, 
as well as pro–MMP-10 during the assembly of 3D tubular 
 networks (Davis et al., 2001; Saunders et al., 2005), which we 
have shown are proregression agents. In the presence of serine 
proteinases, MMP-1 and -10 zymogen activation occurs, and 
active MMP-1 controls collagen and ECM dissolution and col-
lapse of capillary networks. This regression event is completely 
blocked by the presence of suffi cient pericytes (i.e., to deliver 
TIMP-3; Figs. 3–5) or the addition of exogenous TIMP-3 or -2 
(Fig. 1 and Fig. S2). These observations all support the concept 
that the regulation of proteinase activity during angiogenesis 
Figure 7. MT1-MMP is required for EC tube network formation as well as 
invasion and tube formation stimulated by SDF-1𝛂 and S1P. (A–C) ECs 
were treated with the indicated siRNAs and were cultured within collagen 
matrices (A) or on the surface of collagen matrices containing either 
SDF-1α (B) or S1P (C) to stimulate invasion. Quantitation of each condition 
occurred at either 24 (C) or 48 h (A and B). (A) Data are reported 
as the mean number of EC lumens per high-powered ﬁ eld (HPF; A) or 
 invading ECs per high-powered ﬁ eld (B and C) ± SD (error bars; n = 3). 
*, P < 0.01 compared with luciferase control.
Figure 8. MMP-1, MMP-10, and ADAM-15 represent TIMP-2 and -3 tar-
gets involved in EC tubular network regression. ECs were transfected with 
the indicated siRNAs, suspended in 3D collagen matrices, and cultured in 
the presence of 2 μg/ml Plg to initiate EC tubular network regression. 
(A) Cultures were monitored every 4 h for tube regression and collagen gel 
contraction. Data are reported as the mean percent gel contraction ± SD 
(error bars; n = 8). (B) At 96 h, conditioned media from control cultures 
(no Plg) or Plg-treated cultures (+Plg) were collected and analyzed by 
Western blot analysis for MMP-1 and -10 proenzyme (arrow) and activa-
tion (arrowhead) levels.
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(e.g., during wound healing) must be tightly controlled to pre-
vent the regression of newly formed vascular networks. A simi-
lar conclusion was reached in studies of a mouse knockout of 
the MMP inhibitor RECK. An embryonic lethal phenotype 
 occurs at E10.5 secondary to excessive collagenase activity, 
vascular collapse, and hemorrhage (Oh et al., 2001). Marked 
destruction of the collagen scaffold was observed in vivo and 
was associated with defects in vascular tube networks in a 
 manner that was remarkably similar to our previous studies 
(Davis et al., 2001; Saunders et al., 2005).
Our work here shows that distinct metalloproteinases, in-
cluding members of the MMP and ADAM families, infl uence pro-
morphogenic versus proregression events (Fig. 10). Furthermore, 
this study shows that EC-derived TIMP-2 and pericyte-derived 
TIMP-3 play direct roles in regulating these stabilizing effects by 
inhibiting specifi c MMPs and ADAMs. EC-derived molecular 
 targets for TIMP-2 and -3 include MT1-MMP, which appears to 
be the major regulator of EC tube morphogenesis by controlling 
EC invasion and lumen formation. In addition to MT1-MMP, we 
show that MT2-MMP and ADAM-15 appear to contribute to tube 
morphogenesis by regulating the EC invasion of collagen matrices. 
Other targets include MMP-1, MMP-10, and ADAM-15, which act 
together to regulate capillary tube regression.
Pericyte-derived TIMP-3 inhibits EC tube 
formation and vascular assembly in vitro 
and in vivo and stabilizes preexisting EC 
tubular networks
TIMP-3 has previously been reported as an antiangiogenic 
agent and also inhibits the growth of solid tumors (Anand-Apte 
et al., 1997; Spurbeck et al., 2002; Qi et al., 2003). Interestingly, 
TIMP-3 is frequently down-regulated by various tumors through 
methylation of its promoter (Wild et al., 2003). In this study, 
we show that TIMP-3 prevents EC tubular morphogenesis in 
3D matrices in vitro as well as vasculogenesis and vascular re-
modeling in vivo (Figs. 1 and 2). Importantly, TIMP-3 expres-
sion from pericytes was strongly induced by the presence of 
ECs (Fig. 3, A and B) in 3D collagen matrices. We show that 
siRNA suppression of TIMP-3 in pericytes markedly  diminishes 
their ability to stabilize EC-lined tubes that are susceptible to 
Figure 9. The proteinase inhibitory activity of 
TIMP-3 is required for tube stabilization 
through its ability to inhibit EC invasion, tube 
formation, and regression. Generation of sta-
ble EC cell lines expressing GFP, TIMP-1 (T1), 
TIMP-3 (T3) wild-type (WT), and mutants is 
 described in Materials and methods. (A) EC-
conditioned media or cell lysates were ana-
lyzed for TIMP-1 and -3 levels via Western blot 
analysis. (B)  Stable EC cell lines with the indi-
cated expressed constructs were placed on 3D 
collagen matrices and stimulated to invade 
with S1P for 48 h, and, after ﬁ xation, the 
 invasion response was quantitated (n = 3). 
(C) The i ndicated stable EC cell lines were 
 suspended within 3D collagen matrices and al-
lowed to undergo EC tubular network formation 
for 48 h. After ﬁ xation, lumen formation was 
quantitated. (B and C) *, P < 0.01 compared 
with GFP control. (D) EC cell lines were sus-
pended as in C and were cultured in the pres-
ence of 2 μg/ml Plg. Cultures were monitored 
every 4 h for EC tube regression and collagen 
gel contraction. Data are reported as the mean 
percent gel contraction ± SD (error bars; n = 8). 
HPF, high-powered ﬁ eld.
Figure 10. Schematic diagram illustrating the contribution of TIMP-2 and 
-3 to pericyte-induced vascular tube stabilization. As shown, TIMP-2 is 
 derived from ECs, whereas TIMP-3 is produced by pericytes. Together, they 
contribute to vascular stabilization by inhibiting a variety of MMPs, 
ADAMs, and VEGFR-2. The initiation of tube stabilization requires the 
blockade of both EC tube formation and EC tube regression, which further 
leads to the cessation of EC activation and the development of EC quiescence. 
We hypothesize that pericytes are required for ECs to assemble basement 
membrane matrices, which locally capture and present TIMP-3 to ECs 
through heparan sulfate proteoglycans such as perlecan.
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MMP-1–, MMP-10–, and ADAM-15–dependent tube regression 
(Figs. 3–5). This suppression was selective for pericytes  because 
ECs in our system do not express TIMP-3, and this siRNA also 
had no effect when ECs were treated with it. Site-directed 
 mutagenesis of TIMP-3 using treatments known to eliminate 
the proteinase activity of various TIMPs (Brew et al., 2000) 
 interfered with its ability to block both tube formation and 
 regression, showing that these activities depend on its proteinase 
inhibitory function. Pericytes produce TIMP-3 to inhibit EC 
MT1-MMP, MT2-MMP, and ADAM-15, which we have identi-
fi ed as important targets controlling tube morphogenesis. Previous 
studies have revealed important roles for MT1-MMP and 
ADAM-15 in vascular morphogenic events (Horiuchi et al., 
2003; Chun et al., 2004). A fi nal point concerns the known ability 
of TIMP-3 to strongly interact with ECM, such as heparan 
 sulfate in vascular basement membrane matrices (Fig. 10; Davis 
and Senger, 2005). This unique ability of TIMP-3 among the 
TIMPs (Baker et al., 2002) is likely to be important in vascular 
stabilization because of the fact that it will be presented as a 
component of the basement membrane matrix in direct contact 
with endothelium and pericytes in stabilized vessels.
EC-derived TIMP-2 is a regulator of EC 
tube stabilization in 3D collagen matrices
Previous studies indicate that TIMP-2 can block angiogenesis 
through a nonproteinase inhibitory mechanism by binding the 
α3β1 integrin and activating signaling events leading to the in-
hibition of VEGF receptor-2 (VEGFR-2) signaling (Seo et al., 
2003; Stetler-Stevenson and Seo, 2005). In this study, TIMP-2 
appears to block in a similar manner to TIMP-3 (Fig. 1) or to 
chemical inhibitors of surface metalloproteinases such as 
GM6001 (Videos 1–5). In our model, the inhibitory functions 
and vascular stabilizing functions of TIMP-2 appear to occur 
through its proteinase inhibitory function. Supporting this con-
clusion, the siRNA suppression of MT1-MMP expression, a 
key TIMP-2 and -3 target, markedly blocks EC tube formation 
(Fig. 6), and the morphology of MT1-MMP siRNA–treated 
ECs appears remarkably similar to ECs treated with either 
TIMP-2 or -3 in 3D collagen matrices (Figs. 1 C and 6). 
Furthermore, siRNA suppression of TIMP-2 expression in ECs 
can lead to destabilization and MMP-1–dependent regression of 
EC–pericyte cocultures (Fig. 5). Overall, our work with TIMP-2 
as well as TIMP-3 supports the concept that both TIMPs play a 
role in the stabilization of newly formed vessels in 3D matrices.
In addition, TIMP-3 (like TIMP-2) has been reported to 
inhibit VEGFR-2 signaling (Qi et al., 2003). The inhibition of 
VEGFR-2 is a major therapeutic target in antiangiogenic proto-
cols to inhibit excess vascularization in tumors and other con-
texts (Jain, 2005). Interestingly, recent data suggest that 
treatment of angiogenic fi elds with VEGFR-2 antagonists re-
sults in the regression of select vessels followed by the normal-
ization of vasculature, which is a step toward stabilization (Jain, 
2003, 2005). Thus, both TIMP-2 and -3 have been reported to 
regulate VEGFR-2 in addition to their proteinase inhibitory 
 activity. Our work extends these observations in that TIMP-2 
and -3 can act as vascular stabilizing agents by blocking distinct 
proteinases required for tube morphogenesis and regression 
(Fig. 10). Thus, this study, coupled with previous studies 
(Qi et al., 2003; Seo et al., 2003), suggests that EC-derived 
TIMP-2 and pericyte-derived TIMP-3 act through several 
 distinct mechanisms to facilitate vascular stabilization.
Finally, we observe that ECs will continuously undergo 
morphogenesis and lumen formation in 3D matrices unless 
they are provided with a stabilization or stop signal. Without 
this signal, proteinase activities eventually result in the reg-
ression of EC networks. This concept is consistent with a 
proposed target hypothesis (Davis et al., 2002) whereby ECs 
(in a similar fashion to neurons) search for or recruit a target 
cell that provides a stabilizing signal. Pericytes appear to pro-
vide this target function for EC tube networks, which shifts the 
molecular balance from morphogenesis or regression toward 
tube stabilization.
Materials and methods
Reagents
Puriﬁ ed human Plg was obtained from American Diagnostica, Inc. VEGF 
and bFGF were purchased from Upstate Biotechnology. Activated human 
plasmin was obtained from Calbiochem. Puriﬁ ed TIMP-1 (CC3328) and -2 
(CC3327) were obtained from Chemicon. Recombinant human TIMP-3 
(973-TM) and human SDF-1α (CXCL12) were obtained from R&D Systems, 
and the metalloproteinase inhibitor GM600 was obtained from Calbiochem. 
D-erythro-S1P was obtained from Avanti Polar Lipids, Inc. A blocking 
 antibody targeting α2 integrin (BHA2.1) was purchased from Chemicon, 
and a blocking antibody against α5 integrin (mAb 16) was purchased 
from Becton Dickinson. Antibodies targeting MMP-10 (mAb 9101), TIMP-1 
(AF970), TIMP-2 (AF971), ADAM-9 (AF949), and ADAM-15 (AF945) 
were obtained from R&D Systems. Antibodies targeting ADAM-12 (AB 
19133), ADAM-17 (AB 19027), and TIMP-3 (mAb 3318) were obtained 
from Chemicon. A polyclonal antibody against human MT1-MMP (RP1–
MMP-14) was purchased from Triple Point Biologics. The PAI-1 polyclonal 
antibody, MMP-1 mAb (IM35L), and actin mAb (CP01) were purchased 
from Calbiochem. Oligonucleotide primers were obtained from Sigma-
Genosys. All other reagents were purchased from Sigma-Aldrich unless 
otherwise noted. The pAdEasy adenoviral system was obtained from 
B. Vogelstein (Johns Hopkins Medical School, Baltimore, MD), and the 
mRFP construct was obtained from R. Tsien (University of California, 
San Diego, La Jolla, CA).
Cell culture
Human umbilical vein ECs (HUVECs) were purchased from Cambrex and 
were used from passage 2–6. BRPs were cultured in DME containing 10% 
FBS in gelatin-coated ﬂ asks.
BRP isolation
Bovine eyes were obtained from the Rosenthal Center (Texas A&M Univer-
sity), transported on ice, and submerged in Betadine for 10 min before 
 retinas were dissected and placed into sterile buffer. The isolation protocol 
was essentially as previously described (Nayak et al., 1988). At conﬂ u-
ence, pericytes were screened for the expression of 3G5 antigen and 
α-smooth muscle actin.
EC invasion, lumen formation, and regression assays
ECs were placed in 3D invasion assays as described previously (Bayless 
and Davis, 2003), in which ECs invade into 3.75 mg/ml of collagen 
 matrices containing either 1 μM S1P or 200 ng/ml SDF-1α. Alternatively, 
l umen  formation assays were used where individual ECs were suspended 
within 3.75 mg/ml of collagen type I matrices and allowed to assemble 
into 3D networks over time (Davis et al., 2002). Cultures were ﬁ xed at in-
dicated time points with 3% glutaraldehyde in PBS, pH 7.5, for at least 
30 min before additional manipulation. In some cases, cultures were stained 
with 0.1% toluidine blue in 30% methanol and were destained before visu-
alization and photography. Conditioned media were collected to examine 
differential protein expression at various time points. Conditioned media 
were run on SDS-PAGE gels, transferred to polyvinylidene membranes, 
probed, and developed. 3D collagen gels were also extracted in some 
cases to examine protein expression.
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Regression assays were performed as described previously 
(Saunders et al., 2005). For quantitative analysis of gel contraction, 15-μl 
mixtures of ECs and collagen matrix (n = 8 cultures per condition) were 
placed in 384-well tissue culture plates (VWR Scientiﬁ c Products). Cultures 
were allowed to equilibrate for 30 min before the addition of media with 
or without the serine proteases Plg or plasmin. The addition of culture 
 media denoted time zero, and cultures were monitored every 4 h for gel 
contraction. Upon initiation of gel contraction, gel area was recorded us-
ing an ocular grid, and percent collagen gel contraction was calculated as 
follows: [(original area − current gel area)/original area] × 100. When 
contraction was complete, cultures were ﬁ xed or extracted, and media was 
examined for MMP expression and activity. Data are reported as the mean 
percent gel contraction ± SD.
Coculture experiments
Conﬂ uent ECs were resuspended in 3.75 mg/ml of 3D collagen matrices 
at a ﬁ nal concentration of 106 cells/ml. BRPs were incorporated into 
 collagen matrices at varying ratios as indicated. EC or EC/PC cocultures 
(15-μl vol) were evaluated in EC tubular network formation or  quantitative 
regression assays performed in 384-well plates as previously  described 
(Saunders et al., 2005).
Transfection of ECs and pericytes with siRNA
Custom smart pool siRNAs for TIMP-3 and luciferase controls were pur-
chased from Dharmacon and were resuspended (40 μM) in universal buf-
fer and stored at −80°C. siGenome siRNAs targeting TIMP-1, -2, -4, and 
PAI-1 were obtained from Dharmacon and prepared. Transfection of ECs 
with siRNAs before use in experiments was performed essentially as 
 described previously (Saunders et al., 2005). Transfection of BRPs with 
 siRNAs was performed in a similar manner except that LipofectAMINE 
2000 (Invitrogen) was used for transfection. Cells were transfected at a 
 ﬁ nal siRNA concentration of 200 nM.
Mouse embryo culture
CD1 wild-type mouse embryos were dissected at E7.5 and cultured for 
48 h in a continuous gas (5% CO2) rolling embryo culture apparatus. 
Media (0.5 ml/embryo) was changed after 24 h and contained high glucose 
(4.5 g/L) DME (Invitrogen) with 75% immediately centrifuged rat serum 
(Harlan) and glutamine-penicillin-streptomycin (Invitrogen). Recombinant 
TIMP-1 (Chemicon) and -3 (R&D Systems) were added to culture media at 
5 μg/ml, and GM6001 (Calbiochem) was added at 5 μM. Embryos were 
photographed live before whole mount staining with VE-cadherin antibod-
ies (BD Biosciences). RT-PCR analysis and immunohistochemistry were per-
formed as previously described (Lai et al., 2003; Bohnsack et al., 2004). 
Primers used for this analysis were as follows: HPRT, upstream primer (UP) 
(G C T G G T G A A A A G G A C C T C T ) and downstream primer (DN) (C A C A G G-
A C T A G A A C A C C T G C ); TIMP-1, UP (C G A A T C A A C G A G A C C A C C T T ) and 
DN (T G C A G G C A T T G A T G T G A A A T ); and TIMP-3, UP (C A C G G A A G C C T C-
T G A A A G T C ) and DN (C C C A A A A T T G G A G A G C A T G T ).
Preparation of vectors and stable cell lines: cloning and preparation 
of lentiviral vectors
TIMP-1 was ampliﬁ ed from HUVEC cDNA (Bell et al., 2001) using the primers 
TIMP-1 HindIII UP (5′-A G A A G C T T C G A G A T C C A G C G C C C A G A G -3′) 
and TIMP-1 EcoRV DN (5′-A G G A T A T C G C A G G C T T C A G T T C C A C T C -3′). 
TIMP-3 was ampliﬁ ed from human placental cDNA (BD Biosciences and 
CLONTECH Laboratories, Inc.) using the primers TIMP-3 XhoI UP (5′-A G C T C-
G A G G C A A T G A C C C C T T G G C T C G G G C T C A T C -3′) and TIMP-3 XbaI DN 
(5′-A G T C T A G A C G C T C A G G G G T C T G T G G C A T T G -3′). Both inserts were 
initially cloned into the pAdTrack-CMV vector using similar methods that we 
have described previously (Bell et al., 2001). Positive clones were se-
quenced, and protein expression was veriﬁ ed via Western blotting.
The production of recombinant lentivirus was accomplished using the 
pLenti6/V5 TOPO cloning system (Invitrogen). TIMP-1 was ampliﬁ ed from 
the pAdTrack-CMV vector using the primers TIMP-1 pLenti UP (5′-C A C C A T G-
G C C C C C T T T G A G C C C C T G -3′) and TIMP-1 pLenti DN (5′-A G G A T A T C G C A-
G G C T T C A G T T C C A C T C -3′). TIMP-3 was ampliﬁ ed from the pAdTrack-CMV 
vector using the primers TIMP-3 pLenti UP (5′-C A C C A T G A C C C C T T G G C T C-
G G G C T C -3′) and TIMP-3 pLenti DN (5′-A G T C T A G A C G C T C A G G G G T C T-
G T G G C A T T G -3′). Enhanced GFP was ampliﬁ ed from the pEGFP-N2 vector 
(CLONTECH Laboratories, Inc.) using the primers GFP pLenti UP (5′-C A C-
C A T G G T G A G C A A G G G C G A G G -3′) and GFP pLenti DN (5′-A G T C T A G A-
T T A C T T G T A C A G C T -CGTCCATGC-3′). The sequence encoding a modiﬁ ed 
mRFP was ampliﬁ ed from the vector pRSETB (Campbell et al., 2002) using 
the primers mRFP pLenti UP (5′-C A C C A T G G C C T C C T C C G A G G A C G T C -3′) 
and mRFP pLenti DN (5′-A G T T A G G C G C C G G T G G A G T G G C G -3′). Once 
ampliﬁ ed, each insert was TOPO cloned into the pLenti6/V5 TOPO vector. 
After TOPO cloning, One Shot Stbl3 Chemically Competent Escherichia coli 
(Invitrogen) were transformed with DNA according to the manufacturer’s 
protocol. Individual clones containing TIMP-1, TIMP-3, GFP, and mRFP inserts 
were veriﬁ ed via PCR and sequence analysis.
A QuikChange XL Site-Directed Mutagenesis Kit was obtained from Strat-
agene and used to mutate the proteinase inhibitory domain of TIMP-3. PAGE-
puriﬁ ed primers (Sigma-Genosys) were generated as follows: TIMP-3 C1S UP 
(5′-G C G C C G A G G C G T C C A C A T G C T C G C C C A G C C A C -3′) and TIMP-3 C1S 
DN (5′-G T G G C T G G G C G A G C A T G T G G A C G C C T C G G C G C -3′); TIMP-3 
C3S UP (5′-G C G C C G A G G C G T G C A C A T C C T C G C C C A G C C A C -3′) and 
TIMP-3 C3S DN (5′-G T G G C T G G G C G A G G A T G T G C A C G C C T C G G C G C -3′); 
and TIMP-3 C1SC3S UP (5′-G C G C C G A G G C G T C C A C A T C C T C G C C C A G C-
C A C -3′) and TIMP-3 C1SC3S DN (5′-G T G G C T G G G C G A G G A T G T G G A C-
G C C T C G G C G C -3′). Site-directed mutagenesis was performed according 
to the manufacturer’s protocol. Mutated clones were veriﬁ ed via restriction 
digestion, plasmid sequencing, and Western blot analysis.
The 293FT lentiviral packaging cell line was obtained from the 
 ViraPower Lentiviral Gateway Expression Kit (Invitrogen). 293FT cell lines 
were cultured as recommended by the manufacturer in 500 μg/ml G418. 
TIMP-1, -3, wild-type, and mutant isoforms as well as GFP and mRFP lentivi-
ruses were produced according to the manufacturer’s protocol. In brief, a 
T75 ﬂ ask containing 80% conﬂ uent 293FTs in 5 ml of antibiotic-free 
DME/10% FCS was transfected with 4 μg pLenti6/V5-D-TOPO vector and 
12 μg Virapower (Invitrogen) using 36 μl LipofectAMINE 2000 (Invitro-
gen) in 3 ml OptiMEM transfection medium (Invitrogen). The following 
morning, media was removed, and 12 ml of antibiotic-free DME/10% FCS 
was supplied. 293FT cells were allowed to produce lentivirus for 48 h. 
Media containing live lentivirus was collected and spun to remove cell de-
bris before storage at −70°C. Low passage HUVECs or BRPs were al-
lowed to grow to 80% conﬂ uency in T75 ﬂ asks. Cells were infected with 
lentivirus at the following ratio: 3 ml of cell culture media, 6 ml lentiviral su-
pernatant, and polybrene (hexadimethrine bromide) at a ﬁ nal concentra-
tion of 12 μg/ml. Cells were infected for 6 h in this media mixture before 
the addition of another 6 ml of cell culture media. Cells were incubated for 
72 h before the aspiration of media and initiation of stable cell line selec-
tion using Blasticidin (Invitrogen) at a ﬁ nal concentration of 5 (HUVECs) 
or 15 μg/ml (BRPs). Cells were cultured in the presence of Blasticidin for 
10–14 d to ensure stable cell line selection. The expression of respective 
 proteins was veriﬁ ed via Western blot analysis.
Generation of TIMP-3 and MT1-MMP GFP fusion constructs 
and TIMP-3/TIMP-3–GFP adenoviruses
MT1-MMP was ampliﬁ ed from plasmid EX-M0327-M02 (Genecopoeia) con-
taining the full-length cDNA for human MT1-MMP (MMP-14). Standard restric-
tion digestion cloning was performed to clone MT1-MMP into pAdTrack-CMV 
using the primers MT1-MMP HindIII UP (5′-A G A A G C T T G C C A C C A T G T C T C-
C C G C C C C A A G A C C C -3′) and MT1-MMP EcoRV DN (5′-A G G A T A T C T C A-
G A C C T T G T C C A G C A G G G A A C -3′). A positive MT1-MMP pAdTrack clone 
was used as a source template to clone MT1-MMP into the pEGFP-N2 fusion 
vector (CLONTECH Laboratories, Inc.) using the primers MT1-MMP N2 
 HindIII UP (5′-A G A A G C T T G C C A C C A T G T C T C C C G C C C C A A G A C C C C-
C C -3′) and MT1-MMP N2 EcoRI DN (5′-A G G A A T T C G A C C T T G T C C A G C A-
G G G A A C G -3′). Next, the MT1-MMP–GFP fusion construct was cloned into 
the pAdShuttle-CMV expression plasmid using the primers MT1-GFP Ad NotI 
UP (5′-A G G C G G C C G C G C C A C C A T G T C T C C C G C C C C A A G A C C C -3′) and 
MT1-GFP Ad EcoRV DN (5′-A G G A T A T C T T A C T T G T A C A G C T C G T C C A T G -3′). 
At each step, positive clones were veriﬁ ed via PCR, restriction digestion, and 
plasmid sequencing. Furthermore, protein expression was veriﬁ ed via plasmid 
transfection into HEK293 cells for Western blot analysis.
TIMP-3 pAdTrack-CMV was used as a template for the ampliﬁ cation 
of TIMP-3 via standard PCR for cloning into the pEGFP-N2 fusion vector 
(CLONTECH Laboratories, Inc.) using the primers TIMP-3 N2 XhoI UP 
(5′-A G C T C G A G G C A A T G A C C C C T T G G C T C G G G C T C A T C -3′) and TIMP-3 
N2 BamHI DN (5′-A G G G A T C C C G G G G T C T G T G G C A T T G A T G A T G -3′). 
A positive TIMP-3–GFP clone was used as a template to amplify TIMP-3–
GFP for standard cloning into the pAdShuttle-CMV adenoviral vector using 
the primers TIMP-3–GFP pAd Shuttle XhoI UP (5′-A G C T C G A G G C A A T G A-
C C C C T T G G C T C G G G C T C A T C -3′) and TIMP-3–GFP pAd Shuttle EcoRV 
DN (5′-A G G A T A T C C G G G G T C T G T G G C A T T G A T G A T G -3′). At each step, 
positive clones were veriﬁ ed using PCR, restriction digestion, and sequence 
analysis. Additionally, clones were transfected, and visualization of GFP 
fusion proteins was veriﬁ ed via ﬂ uorescent microscopy, transfection of plas-
mids into HEK293 cells, and Western blot analysis of TIMP-3 and TIMP-3–
GFP proteins. Recombinant adenoviruses encoding TIMP-3 and TIMP-3–GFP 
JCB • VOLUME 175 • NUMBER 1 • 2006 190 
were generated from expression plasmids TIMP-3 pAdTrack-CMV and 
TIMP-3–GFP pAdShuttle-CMV via recombination with the pAdEasy adeno-
viral vector as described previously (Bell et al., 2001).
Cotransfection of TIMP-2, TIMP-3, and MT1-MMP constructs in HEK293 
cells for ELISA
HEK293 cells were cultured to 95% conﬂ uence in DME/10% FCS in 12-well 
plates precoated with 20 μg/ml of collagen type I. LipofectAMINE 
2000 was used to cotransfect cells with 750 ng pLenti plasmids encoding 
TIMP-2 or -3 in combination with 750 ng of plasmids MT1-MMP pAdTrack 
or MT1-MMP–GFP pAdShuttle encoding MT1-MMP or MT1-MMP–GFP 
(1.5 μg of total DNA per well). Transfected HEK293 cells were allowed to 
recover for 24 h, and transfection efﬁ ciency was veriﬁ ed via ﬂ uorescent 
microscopy. Detergent lysates of cotransfected HEK293 cells were made 
using chilled (4°C) 2% Triton X-100 in 1× TBS, pH 8.0, containing com-
plete EDTA-free protease inhibitor cocktail tablets (Roche Diagnostics). 
 Before cell lysis, 12-well plates were washed once with 1.0 ml of warm, 
serum-free DME and placed on ice. Each well was lysed with 500 μl of 
cold lysis buffer. Lysates were transferred to 1.7-ml Eppendorf tubes and in-
cubated on ice for 20 min before centrifugation at 20,000 rpm for 20 min 
at 4°C to pellet-insoluble cellular debris. Supernatants were removed and 
stored at −70°C until use.
A mAb (3E6) against GFP used to capture GFP fusion proteins was 
obtained from Qbiogene. Polystyrene microwell plates (VWR Scientiﬁ c 
 Products) were precoated with or without 2 μg/ml anti-GFP antibody in 
PBS overnight at 4°C. The following morning, plates were warmed to room 
temperature, aspirated to remove residual GFP antibody, and blocked in 
Tris–Tween 20 detergent solution for 20 min. HEK293 cell cotransfection 
lysates were diluted 1:2 with Tris–Tween 20 containing 1% BSA and incu-
bated at 100 μl/well vol for 2 h at room temperature. Lysates were aspi-
rated, and plates were washed four times in Tris–Tween 20 before 
incubation with polyclonal antibodies (50 μl/well) against TIMP-2 or -3 
(R&D Systems) diluted at 1:200 and 1:100, respectively, in Tris–Tween 20 
and 1% BSA. In separate wells, a control antibody targeting MT1-MMP 
(Triple Point Biologics) was used to ensure the proper capture of MT1-
MMP–GFP and not MT1-MMP pAdTrack. Additionally, conditioned media 
and lysates were assessed via Western blotting to ensure the proper pro-
tein expression of each transfection condition. Primary antibodies were in-
cubated for 1 h at room temperature, aspirated, and plates were washed 
four times before the addition of HRP-conjugated secondary antibodies 
(50 μl/well; DakoCytomation) diluted 1:2,000 in Tris–Tween 20 and 1% 
BSA. Secondary antibodies were incubated for 30 min at room tempera-
ture before washing three times in Tris–Tween 20 and were washed twice 
in ddH2O. ELISA plates were developed using a typical O- phenylenediamine 
substrate solution (100 μl/well) and stopped with 100 μl/well of 1 M 
 sulfuric acid before the measurement of absorbance at 490 nm. Data are 
reported as the mean absorbance for duplicate wells and have been 
 background corrected against control wells, which were not precoated 
with the capturing GFP mAb.
Infection of HUVECs with TIMP-3 and TIMP-3–GFP adenoviruses for ELISA 
capture and detection of EC-derived MT1-MMP
HUVECs were cultured to conﬂ uence in T25 ﬂ asks. Viral transformation of 
ECs with recombinant adenoviruses encoding TIMP-3 or TIMP-3–GFP  fusion 
was performed as described previously (Bell et al., 2001). The following 
morning, transformation efﬁ ciency was assessed using ﬂ uorescent micro-
scopy. Flasks were washed twice with 3 ml of warm M199, and detergent 
lysates of TIMP-3– and TIMP-3–GFP-producing ECs were prepared using 
1.5 ml of cold lysis buffer per T25 ﬂ ask. The ELISA capture technique was 
performed as described above except that for HUVEC lysates, TIMP-3–GFP 
was captured, and lysates were probed for the EC-derived target MT1-MMP. 
The MT1-MMP polyclonal antibody (Triple Point Biologics) was used at a 
1:200 dilution. Data are reported as the mean absorbance for duplicate 
wells and have been background corrected against control wells, which 
were not precoated with the capturing GFP mAb.
Microscopy and imaging
A ﬂ uorescence inverted microscope (Eclipse TE2000-U; Nikon) was used 
to visualize EC invasion, vasculogenesis, and regression as well as immuno-
ﬂ uorescence microscopy. Lenses used for time lapse included a CFI plan-
Fluor 20× with an NA of 0.45, whereas for immunoﬂ uorescence, a CFI 
plan-Apo 60× oil objective with an NA of 1.4 was used. FITC and rhoda-
mine were used for immunoﬂ uorescence, whereas GFP and mRFP were 
used for still photographs of EC–pericyte cocultures. Imaging media in-
cluded Slow Fade (Invitrogen) for immunoﬂ uorescence and M199 culture 
media without phenol red for all time lapses of EC cultures and still photog-
raphy of EC–pericyte cultures. Imaging of cocultures used an inverted mi-
croscope (CKX41; Olympus) and 20× NA 0.45 Luc plan FLN or 40× NA 
0.6 Luc Plan FL objectives. Images were acquired using a camera (DP70; 
Olympus) and DP manager software version 2.1.1.163 (Olympus). Time-
lapse imaging of living cells used the Eclipse microscope and was per-
formed with a temperature-controlled chamber (Solent Scientiﬁ c) set to 
37°C with continuous ﬂ ow of 5% CO2. Time-lapse two-photon imaging was 
performed at the lowest possible excitation levels. Images were captured 
 every 10 min in single z planes with a monochromatic camera (CoolSNAP 
HQ; Photometrics) and a 6.45 × 6.45-μm pixel pitch (Photometrics) using 
MetaMorph software (Molecular Devices). After image acquisition, stacks of 
each stage position were assembled using MetaMorph software.
Statistical analysis
Statistical analysis of selected EC invasion, vasculogenesis, and regression 
data was performed using SPSS 11.0 software (SPSS, Inc.). Analysis of 
variance was used to compare means when analyzing more than two 
groups. The Tukey’s post-hoc test was used to determine groups of  similarity. 
Statistical signiﬁ cance was set at P < 0.01. Unpaired t tests were used 
when analyzing two groups within a single experiment.
Online supplemental material
Fig. S1 shows that EC invasion of 3D collagen matrices is markedly in-
hibited by ECs expressing TIMP-3 but not by ECs expressing TIMP-1 and 
that pericytes are an abundant source of TIMP-3. Fig. S2 shows that TIMP-3 
stabilizes ECs undergoing EC tubular network formation or regression, 
whereas anti–α2-integrin–blocking antibodies cause the rapid collapse 
of EC tubular networks. Fig. S3 shows that TIMP-3 blocks further lumen 
development and network remodeling when added to preexisting EC 
tubular networks without causing the collapse of these structures. Fig. S4 
shows that the suppression of membrane-associated metalloproteinases via 
siRNAs in ECs indicates a critical role for MT1-MMP in the S1P- mediated 
invasion of 3D collagen matrices. Fig. S5 shows that the suppression of 
membrane-associated metalloproteinases via siRNAs in ECs indicates 
a critical role for MT1-MMP, MT2-MMP, and ADAM-15 in the SDF-1α–
 mediated invasion of 3D collagen matrices. Video 1 is a time-lapse video 
of control EC tube morphogenesis in 3D collagen matrices. Video 2 is 
a time-lapse video of normal EC tube morphogenesis in the presence of 
TIMP-1 in 3D collagen matrices. Videos 3 and 4 are time-lapse videos of 
the blockade of EC tube morphogenesis by TIMP-2 and -3, respectively, 
in 3D collagen matrices. Video 5 is a time-lapse video of the blockade of 
EC tube morphogenesis by the MMP inhibitor GM6001 in 3D collagen 
matrices. Online supplemental material is available at http://www.jcb.
org/cgi/content/full/jcb.200603176/DC1.
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